Terms: = Kidney tumors AND REL, I-Rel, 5966, ENSG00000162924, C-Rel
12 results:
1. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).
Chen RC; Choueiri TK; Feuilly M; Meng J; Lister J; Marteau F; Falchook AD; Morris MJ; George DJ; Feldman DR
Cancer; 2020 Dec; 126(24):5311-5318. PubMed ID: 33022096
[TBL] [Abstract] [Full Text] [Related]
2. A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC).
Shah R; Botteman M; Solem CT; Luo L; Doan J; Cella D; Motzer RJ
Clin Genitourin Cancer; 2019 Oct; 17(5):356-365.e1. PubMed ID: 31272883
[TBL] [Abstract] [Full Text] [Related]
3. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
[TBL] [Abstract] [Full Text] [Related]
4. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Khandani AH; Cowey CL; Moore DT; Gohil H; Rathmell WK
Nucl Med Commun; 2012 Sep; 33(9):967-73. PubMed ID: 22714005
[TBL] [Abstract] [Full Text] [Related]
5. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.
Zbrozek AS; Hudes G; Levy D; Strahs A; Berkenblit A; DeMarinis R; Parasuraman S
Pharmacoeconomics; 2010; 28(7):577-84. PubMed ID: 20550223
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma.
Morais C; Healy H; Johnson DW; Gobe G
Nephrol Dial Transplant; 2010 May; 25(5):1462-74. PubMed ID: 20037166
[TBL] [Abstract] [Full Text] [Related]
7. MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer.
Boyd S; Virolainen S; Pärssinen J; Skoog T; van Hogerlinden M; Latonen L; Kyllönen L; Toftgard R; Saarialho-Kere U
Exp Dermatol; 2009 Dec; 18(12):1044-52. PubMed ID: 19601983
[TBL] [Abstract] [Full Text] [Related]
8. Mutation of an IKK phosphorylation site within the transactivation domain of rel in two patients with B-cell lymphoma enhances rel's in vitro transforming activity.
Starczynowski DT; Trautmann H; Pott C; Harder L; Arnold N; Africa JA; Leeman JR; Siebert R; Gilmore TD
Oncogene; 2007 Apr; 26(19):2685-94. PubMed ID: 17072339
[TBL] [Abstract] [Full Text] [Related]
9. Ataxia telangiectasia-mutated, a DNA damage-inducible kinase, contributes to high NaCl-induced nuclear localization of transcription factor TonEBP/OREBP.
Zhang Z; Ferraris JD; Irarrazabal CE; Dmitrieva NI; Park JH; Burg MB
Am J Physiol Renal Physiol; 2005 Sep; 289(3):F506-11. PubMed ID: 15840767
[TBL] [Abstract] [Full Text] [Related]
10. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
An J; Sun Y; Fisher M; Rettig MB
Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
[TBL] [Abstract] [Full Text] [Related]
11. Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha.
Ling W; Rayman P; Uzzo R; Clark P; Kim HJ; Tubbs R; Novick A; Bukowski R; Hamilton T; Finke J
Blood; 1998 Aug; 92(4):1334-41. PubMed ID: 9694722
[TBL] [Abstract] [Full Text] [Related]
12. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report.
Li X; Liu J; Park JK; Hamilton TA; Rayman P; Klein E; Edinger M; Tubbs R; Bukowski R; Finke J
Cancer Res; 1994 Oct; 54(20):5424-9. PubMed ID: 7923175
[TBL] [Abstract] [Full Text] [Related]
